Last updated: August 25, 2026
Croscarmellose sodium is a mature, globally traded pharmaceutical excipient used primarily as a superdisintegrant in tablets and capsules. Its financial outlook is tied to oral solid-dose drug volumes, generic manufacturing, direct-compression adoption, and supplier qualification requirements rather than to new molecular patents. Public companies generally do not disclose croscarmellose sodium revenue separately, so market-size estimates must be treated as modeled rather than audited figures.
What is croscarmellose sodium and how is it used?
Croscarmellose sodium is a cross-linked, internally linked sodium carboxymethylcellulose. It promotes rapid tablet breakup by absorbing water and expanding within the dosage form. The material is used in immediate-release tablets, orally disintegrating tablets, capsules, and some chewable products.
Its main commercial value is performance consistency at relatively low use levels. Formulators commonly use it at approximately 0.5% to 5% of tablet weight, although the effective concentration depends on particle size, grade, compression force, granulation process, and the drug formulation. [1]
Key technical properties
| Attribute |
Commercial relevance |
| Excipient class |
Superdisintegrant |
| Primary function |
Promotes tablet disintegration |
| Typical dosage forms |
Immediate-release tablets, capsules, ODTs |
| Chemical basis |
Cross-linked sodium carboxymethylcellulose |
| CAS number |
74811-65-7 |
| Regulatory status |
Widely accepted pharmaceutical inactive ingredient |
| Main competing excipients |
Crospovidone and sodium starch glycolate |
| Main demand driver |
Oral solid-dose production |
| Main switching barrier |
Formulation requalification and dissolution comparability |
Croscarmellose sodium is not an active pharmaceutical ingredient and does not create therapeutic exclusivity. Its value comes from consistent particle morphology, swelling performance, microbial control, low impurity levels, documentation, and supply reliability.
How large is the croscarmellose sodium market?
No consolidated, audited public market figure exists for croscarmellose sodium alone. Public market-research estimates often combine several pharmaceutical excipient categories, including disintegrants, binders, fillers, lubricants, and coating materials. Those figures cannot be used as direct croscarmellose sodium revenue.
A practical market model places croscarmellose sodium in a small but recurring segment of the pharmaceutical excipient industry. Demand is distributed across branded drugs, generic medicines, contract manufacturing, and over-the-counter products. Volume is materially larger than the specialty-price positioning might suggest because the ingredient is used in high numbers of tablets worldwide.
Demand structure
| Demand segment |
Impact on croscarmellose sodium |
| Generic immediate-release tablets |
Largest volume contributor |
| Branded oral solid products |
Supports higher documentation and grade requirements |
| Contract development and manufacturing |
Increases demand for qualified, multi-region suppliers |
| Orally disintegrating tablets |
Supports premium grades and formulation expertise |
| Nutraceuticals |
Expands demand but can carry lower qualification barriers |
| Injectable and biologic products |
Limited direct relevance |
The strongest structural demand driver is the continued scale of generic oral solid-dose manufacturing. Croscarmellose sodium is also used in reformulation programs where developers seek faster disintegration without changing the active ingredient.
What is the financial trajectory for croscarmellose sodium?
The financial trajectory is likely to be steady rather than explosive. Volume growth should track tablet production, while revenue growth depends on price realization, qualification of premium grades, raw-material costs, and geographic mix.
A useful indexed scenario model is shown below. The index sets 2024 revenue at 100 and applies modeled annual growth rates. It is not reported industry revenue.
| Scenario |
Modeled annual growth |
2029 revenue index |
Commercial interpretation |
| Low |
3% |
116 |
Mature-volume growth with pricing pressure |
| Base |
6% |
134 |
Generic growth plus moderate premiumization |
| High |
9% |
154 |
Strong emerging-market demand and premium-grade expansion |
The base case assumes that volume growth remains positive, suppliers recover a portion of inflation, and high-specification grades gain share. The low case reflects commodity competition, customer concentration, and price erosion. The high case requires sustained expansion in generic tablets, regional manufacturing capacity, and faster uptake of high-performance formulations.
Revenue drivers
Croscarmellose sodium suppliers generate revenue through four main channels:
- Volume sold to tablet and capsule manufacturers.
- Premium pricing for consistent, narrow-specification grades.
- Technical support and formulation services.
- Long-term supply agreements with qualified pharmaceutical customers.
The market does not have the same pricing power as patented active ingredients. Once a supplier and grade are approved, switching is operationally difficult, but customers can apply price pressure during procurement cycles. Qualification creates retention value, not monopoly pricing.
Cost structure
The major cost inputs include cellulose feedstock, sodium hydroxide and other processing chemicals, water, energy, labor, quality testing, packaging, and freight. Cellulose availability and energy costs affect gross margin. Regulatory testing and documentation increase fixed costs but are necessary to supply regulated drug manufacturers.
Supplier margin performance is likely to diverge by grade:
- Standard grades face greater price competition.
- Premium grades command stronger margins when they improve disintegration, dissolution, flow, or compressibility.
- Small-volume specialty grades carry higher unit costs.
- Regionally produced material may reduce freight exposure but require additional customer qualification.
Which companies supply croscarmellose sodium?
The market includes multinational excipient manufacturers, specialty cellulose producers, and regional pharmaceutical-material suppliers. Product availability varies by country and grade.
| Supplier or brand family |
Market position |
| IFF, including the Ac-Di-Sol product family |
Established pharmaceutical excipient supplier with global customer reach |
| JRS Pharma, including VIVASOL grades |
Pharmaceutical excipient and functional cellulose supplier |
| DFE Pharma and regional partners |
Supplier of functional excipients and formulation support |
| Ashland and other cellulose-specialty suppliers |
Relevant in cellulose-derived pharmaceutical materials |
| Regional manufacturers in China and India |
Competitive on price and regional availability |
Brand ownership and distribution arrangements can change through acquisitions, divestitures, licensing, and regional agency agreements. Procurement teams should verify current legal manufacturer, manufacturing site, quality agreement, and certificate-of-analysis issuer for each grade.
How concentrated is supply?
Supply is moderately concentrated at the high-compliance end and more fragmented in commodity and regional channels. Large pharmaceutical manufacturers often maintain at least two qualified sources, but dual sourcing is not always operationally simple. Differences in bulk density, substitution level, particle size, moisture, and swelling behavior can alter tablet performance.
The effective supplier market is therefore smaller than the list of companies offering nominally equivalent croscarmellose sodium. A supplier with an accepted grade, strong change-control history, and regulatory documentation has an advantage over a low-cost producer that has not completed customer qualification.
What patents protect croscarmellose sodium?
No current, broadly applicable composition-of-matter patent is generally associated with the basic use of croscarmellose sodium as a pharmaceutical superdisintegrant. The material is a mature excipient technology.
Relevant intellectual-property protection may still exist around:
- Manufacturing processes.
- Cross-linking conditions.
- Particle-size distributions.
- Surface treatments.
- Co-processed excipient systems.
- Specific tablet formulations.
- Delivery systems combining croscarmellose sodium with an active ingredient.
- Supplier trademarks and proprietary grade names.
Patent protection must be assessed at the product or formulation level rather than assumed from the excipient name. A drug patent that claims a tablet containing croscarmellose sodium may protect the finished formulation, but it does not create exclusivity over the excipient itself.
How strong is the patent estate?
The standalone patent estate for croscarmellose sodium is weak from a market-exclusivity perspective because the core material is established and has multiple suppliers. The stronger barriers are regulatory and technical:
| Barrier |
Relative strength |
| Core excipient patent |
Low |
| Supplier trademark |
Moderate |
| Manufacturing know-how |
Moderate to high |
| Customer qualification history |
High |
| Formulation-specific patent |
Variable |
| Regulatory documentation |
High in regulated markets |
| Supply continuity |
High for approved products |
Manufacturing know-how can remain commercially important even when patents have expired or are absent. Process control determines substitution level, cross-link density, particle morphology, moisture profile, and performance in different manufacturing methods.
What is the FDA regulatory status of croscarmellose sodium?
Croscarmellose sodium is a widely used pharmaceutical inactive ingredient and appears in the FDA Inactive Ingredient Database for approved drug products. Its use is evaluated by route, dosage form, and maximum potency information recorded in the database. [2]
The material is also covered by pharmacopeial standards, including the United States Pharmacopeia and National Formulary. Pharmaceutical manufacturers typically assess identity, purity, loss on drying or water content, viscosity-related properties, microbial quality, elemental impurities, and functionality against the applicable specification. [3]
Is croscarmellose sodium in the Orange Book?
Croscarmellose sodium is not independently listed in the FDA Orange Book because the Orange Book covers approved drug products and their patents or exclusivity, not standalone excipients. [4]
An Orange Book-listed tablet may contain croscarmellose sodium, but any patent listing relates to the drug product, method of use, formulation, or device. It does not grant Orange Book exclusivity to the excipient supplier.
Does croscarmellose sodium have regulatory exclusivity?
No. Croscarmellose sodium does not receive new chemical entity exclusivity, orphan-drug exclusivity, pediatric exclusivity, or biologic exclusivity. Those protections apply to qualifying drug products, not mature inactive ingredients.
Are Paragraph IV challenges relevant to croscarmellose sodium?
Paragraph IV litigation is generally not relevant to the excipient itself. A generic manufacturer may file a Paragraph IV certification against a patent covering a drug product that contains croscarmellose sodium, but the challenge concerns the drug patent rather than the excipient.
The excipient can influence litigation indirectly if a formulation patent claims a particular disintegrant, particle-size range, concentration, or performance outcome. Those cases are product-specific and cannot be generalized across the croscarmellose sodium market.
What formulation patents use croscarmellose sodium?
Formulation patents may claim croscarmellose sodium as one element of a tablet composition. Common claim themes include:
- Immediate-release profiles.
- Rapid disintegration.
- Improved dissolution of poorly soluble drugs.
- Low-dose uniformity.
- Orally disintegrating tablets.
- Abuse-deterrent or tamper-resistant formulations.
- Specific compression and granulation conditions.
- Combination excipient systems.
The commercial value of such patents depends on whether the claims require croscarmellose sodium specifically or allow substitution with crospovidone, sodium starch glycolate, or another disintegrant. Narrow claims may be easier to design around but harder to invalidate only when supported by strong formulation data.
When does croscarmellose sodium lose exclusivity?
Croscarmellose sodium has no single exclusivity-loss date. Its underlying technology is mature, and multiple manufacturers can produce it. Commercial competition is governed by manufacturing capability, customer qualification, pharmacopeial compliance, and procurement contracts.
A particular supplier may lose protection over a process patent or proprietary formulation technology on a patent-by-patent basis. A finished drug containing croscarmellose sodium loses exclusivity according to the drug product’s patents and regulatory exclusivities, not according to the excipient’s history.
What generic entry risks exist for croscarmellose sodium suppliers?
The principal risks are commercial rather than patent-driven.
Price erosion
Generic manufacturers typically purchase excipients through competitive tenders. Standard croscarmellose sodium grades can face substitution pressure when customers have approved multiple sources.
Supplier substitution
Changing supplier or grade may require comparative testing, stability work, process validation, dissolution assessment, and regulatory documentation. These requirements slow substitution but do not prevent it.
Raw-material volatility
Cellulose and chemical-input costs can compress margins when contracts do not permit pass-through pricing. Freight and energy costs are material for cross-border supply.
Regional manufacturing
Chinese, Indian, and other regional suppliers can compete aggressively on price. Their market penetration depends on regulatory documentation, consistency, inspection history, and acceptance by multinational drug manufacturers.
Formulation substitution
Crospovidone and sodium starch glycolate compete directly with croscarmellose sodium. A formulation developer may switch when another superdisintegrant delivers better flow, faster disintegration, lower sensitivity to compression force, or a lower total cost.
How does croscarmellose sodium compare with competing superdisintegrants?
| Attribute |
Croscarmellose sodium |
Crospovidone |
Sodium starch glycolate |
| Main material |
Cross-linked cellulose derivative |
Cross-linked polyvinylpyrrolidone |
Cross-linked starch derivative |
| Water uptake |
High |
High, with strong capillary action |
High swelling |
| Common application |
Immediate-release tablets |
Tablets and ODTs |
Immediate-release tablets |
| Key advantage |
Strong swelling and broad formulation utility |
Good wicking and low gelling tendency |
Effective swelling at low concentrations |
| Main limitation |
Grade-dependent performance and cellulose variability |
Polymer-source and particle-property variation |
Potential gelling or slower performance in some systems |
| Switching burden |
Requires formulation testing |
Requires formulation testing |
Requires formulation testing |
No superdisintegrant is universally interchangeable. A change can affect tablet hardness, friability, disintegration, dissolution, content uniformity, and stability.
What licensing deals affect the market?
Publicly disclosed licensing deals specific to croscarmellose sodium are limited. Commercial arrangements more often involve distribution, private-label manufacturing, regional representation, or supply agreements than patent licenses.
The relevant transaction risks are:
- Change in legal manufacturer.
- Loss of an authorized distributor.
- Transfer of manufacturing equipment or site.
- Revised quality agreements.
- New regulatory filings after an ownership change.
- Supply commitments linked to minimum purchase volumes.
Drug companies should distinguish a branded excipient license from a distribution agreement. A distribution agreement normally does not transfer manufacturing know-how or provide exclusivity over the underlying technology.
What manufacturing and IP barriers affect new entrants?
A new entrant must establish more than chemical identity. The practical entry barriers include validated process control, batch-to-batch functionality, microbial control, analytical methods, packaging integrity, regulatory support, and a documented change-control system.
Manufacturing requirements
Critical process variables may include:
- Degree and uniformity of cross-linking.
- Substitution level.
- Particle-size distribution.
- Moisture content.
- Bulk and tapped density.
- Swelling capacity.
- Flow properties.
- Residual process chemicals.
- Microbial limits.
A material can meet a basic chemical specification and still fail customer qualification because its compression or disintegration behavior differs from the incumbent grade.
Geographic coverage
North America and Europe impose demanding documentation and supplier-audit expectations. India and China are major pharmaceutical manufacturing bases and important sources of excipient demand. Emerging markets can provide volume growth but may show greater price sensitivity and more fragmented distribution.
Regional production reduces freight exposure and improves delivery times. It can also create multi-site qualification burdens if the supplier changes production location.
What is the commercial outlook through 2029?
The base commercial outlook is moderate growth with margin differentiation.
| Period |
Expected market condition |
| 2025-2026 |
Stable demand, continued procurement pressure, normalization of freight and input costs |
| 2027-2028 |
Increased qualification of regional suppliers and continued generic tablet growth |
| 2029 |
Greater separation between commodity grades and high-performance, documentation-intensive grades |
The strongest suppliers will likely be those with multinational regulatory coverage, multiple manufacturing sites, formulation support, and a portfolio broader than one excipient. A single-product supplier remains exposed to price competition and customer concentration.
Revenue growth should be more resilient for suppliers serving regulated branded products, complex generics, and ODT developers. Commodity exposure will generate lower margins and higher volatility.
Key Takeaways
- Croscarmellose sodium is a mature superdisintegrant used mainly in tablets and capsules.
- Its market growth is linked to oral solid-dose and generic drug production.
- Public filings do not separately report croscarmellose sodium revenue, so market-size figures are modeled rather than audited.
- The excipient has no meaningful standalone regulatory exclusivity and is not independently listed in the Orange Book.
- Core patent risk is low; manufacturing know-how, customer qualification, and formulation patents are more important.
- Crospovidone and sodium starch glycolate are the principal substitutes.
- Standard grades face price pressure, while high-performance grades benefit from qualification and technical-service barriers.
- A modeled 2024-2029 revenue index ranges from 116 in a low-growth case to 154 in a high-growth case.
- Generic drug volume, supplier diversification, raw-material costs, and regulatory compliance will determine financial performance.
FAQs
Is croscarmellose sodium the same as sodium carboxymethylcellulose?
No. Croscarmellose sodium is a cross-linked form of sodium carboxymethylcellulose designed to function primarily as a superdisintegrant. Conventional sodium carboxymethylcellulose is used for different viscosity, binding, thickening, or stabilizing functions.
Is croscarmellose sodium safe in pharmaceutical tablets?
It is a widely used pharmaceutical inactive ingredient accepted in approved drug products. Safety assessment remains product-specific and depends on route, dose, formulation, and regulatory requirements. [2]
Can a generic manufacturer substitute crospovidone for croscarmellose sodium?
Possibly, but substitution requires formulation development and comparative testing. The change may affect disintegration, dissolution, tablet strength, friability, and stability.
Does croscarmellose sodium qualify for a drug master file?
Suppliers may maintain regulatory-support files or drug master files depending on jurisdiction and customer strategy. The existence, format, and availability of such documentation must be confirmed with the supplier.
Which croscarmellose sodium grade is best for direct compression?
No single grade is universally best. Selection depends on particle size, flow, compactability, swelling behavior, drug loading, compression force, and the target dissolution profile. Grade selection should be based on comparative formulation data.
References
-
Rowe, R. C., Sheskey, P. J., & Quinn, M. E. (Eds.). (2020). Handbook of pharmaceutical excipients (9th ed.). Pharmaceutical Press.
-
U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
-
United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Croscarmellose sodium monograph. United States Pharmacopeial Convention.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
